Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain - Nature Chemical Biology
www.nature.com
Using directed evolution and structure-guided design, human synthetic antibodies selective to HER2 point mutants were developed. The use of the antibodies as T cell engagers killed HER2-mutant cancer cells while sparing HER2-wild-type normal cells.
This is an automated archive made by the Lemmit Bot.

The original was posted on /r/science by /u/chrisdh79 on 2024-10-23 12:30:13+00:00.

Original Title: NYU develops new drug that attacks cancer cells without harming healthy ones by developing antibodies that recognize only mutant HER2 in human cell lines and in mouse models | Researchers say the technique may lead to new ways to treat patients with some cancers with minimal side effects.